GlassScriptPhysician profile
Jon Avery Tan Go
NPI 1134351950
$26,983.76
in general payments reported to CMS, 2019-2025
46 companies · $3,472 in 2025
The $3,472 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,329 · 2020: $3,163 · 2021: $4,207 · 2022: $3,296 · 2023: $3,806 · 2024: $4,711 · 2025: $3,472.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Honoraria: $805.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,185.15 |
| Honoraria | $805.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $5,899.13 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $2,911.29 | 2019-2025 | |
| Amgen INC. | $2,610.19 | 2019-2025 | Tavneos, Tepezza, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $1,795.11 | 2021-2025 | |
| Horizon Therapeutics Plc | $1,638.98 | 2019-2023 | Krystexxa, Tepezza |
| Lilly USA, LLC | $1,385.99 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,339.63 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Glaxosmithkline, LLC. | $1,015.92 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Boston Scientific Corporation | $642.66 | 2019-2025 | Wavewriter Alpha Prime 16, General - Pain Management, Watchman Access System |
| Novo Nordisk INC | $549.42 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Travere Therapeutics, INC. | $542.19 | 2023-2025 | Filspari |
| Janssen Pharmaceuticals, INC | $535.70 | 2019-2023 | Xarelto |
| Allergan, INC. | $533.97 | 2019-2020 | |
| Amarin Pharma, INC. | $523.58 | 2020-2022 | |
| Kowa Pharmaceuticals America, INC. | $447.86 | 2019-2024 | Zoryve |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $427.88 | 2020-2025 | Nexletol |
| Merck Sharp & Dohme LLC | $383.02 | 2019-2025 | Capvaxive, Gardasil 9, M-M-R II |
| Calliditas Therapeutics US INC. | $381.62 | 2023-2025 | Tarpeyo |
| Pfizer INC. | $326.54 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $318.06 | 2019-2022 | |
| Ardelyx, INC. | $250.55 | 2024-2025 | Xphozah 30 Mg |
| Aurinia Pharma U.S., INC. | $249.50 | 2022-2023 | Lupkynis |
| Arbor Pharmaceuticals, INC. | $228.70 | 2019-2021 | |
| Radius Health, INC. | $212.51 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $194.01 | 2019-2023 | |
| Genentech USA, INC. | $172.66 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $163.19 | 2019-2020 | |
| Ani Pharmaceuticals, INC. | $142.24 | 2025 | Purified Cortrophin Gel |
| Ironwood Pharmaceuticals, INC | $139.27 | 2019-2020 | |
| Kyowa Kirin, INC. | $125.00 | 2024 | Crysvita |
| Corcept Therapeutics | $115.00 | 2025 | Korlym |
| Dexcom, INC. | $108.67 | 2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $94.95 | 2021-2023 | Freestyle Libre 3 |
| Vifor Pharma, INC. | $86.48 | 2019-2020 | |
| Exact Sciences Corporation | $82.70 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Biohaven Pharmaceuticals, INC. | $74.37 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $70.60 | 2023-2025 | Eliquis |
| Insmed, INC. | $70.39 | 2019-2021 | |
| Astellas Pharma US INC | $38.43 | 2021-2023 | Myrbetriq |
| Madrigal Pharmaceuticals | $27.44 | 2025 | Rezdiffra |
| Eisai INC. | $26.05 | 2021 | |
| Agios Pharmaceuticals, INC. | $25.61 | 2025 | |
| Neurelis, INC. | $25.54 | 2022 | |
| Dermavant Sciences, INC. | $20.23 | 2022 | |
| Leo Pharma INC. | $16.64 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.29 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jon Avery Go listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.